Published in Cancer Weekly, June 4th, 2002
The phase I study will assess the safety and tolerability of escalating doses of CpG 7909. Once these are established, a phase II group of patients will be enrolled to determine overall tumor response and immunologic effects. Other endpoints of the phase II portion of the study include time to disease progression, duration of response and survival time.
"Because our CpG 7909 product candidate stimulates multiple...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.